MediciNova, Inc.
  Message from CEO
  Our Mission
  Company Profile
  Management Team
  History
  Ongoing Clinical Studies
    About MN-166 (Ibudilast)
    ALS
    Oncology / Glioblastoma
    DCM
    CIPN
    ARDS / Lung Injury
    About MN-001(Tipelukast)
    NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  Press Release
  Event
  Media Archive
  Annual Report
  SEC filing
  Stock Quote -TSE
  Stock Quote -Nasdaq
  Historical Price Lookup
  Investment Calculator
  Analyst Coverage
  Corporate Governance
  Information Request
  Corporate Presentation & Resarch Reports
    Progressive Multiple Sclerosis (Progressive MS)
    Amyotrophic Lateral Sclerosis (ALS)
    Oncology / Glioblastoma
    Substance Dependence and Addiction
    MN-166 (ibudilast) News Articles
    MN-166 (ibudilast) Publications
  MN-001 Presentation
  Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001(Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Investor Relations
    • Press Release
    • Event
    • Media Archive
    • Annual Report
    • SEC filing
    • Stock Quote -TSE
    • Stock Quote -Nasdaq
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
    • Corporate Governance
    • Information Request
  • Presentation
    • Corporate Presentation and Equity Research Analyst Reports
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Contact Us

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MN-166
2024.09.092025.09.25
Page Top
medicinova_en
MediciNova, Inc.

関連記事

MN-001

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe

MN-166

MN-166のオピオイド依存症治療を適応とするフェーズ2a臨床治験に関して第77回アメリカ薬物依存症学会年次総会での発表のお知らせ

MN-166

MN-166のメタンフェタミン(覚醒剤)依存症を適応とするフェーズ1b臨床治験結果のDrug and Alcohol Dependence への論文掲載のお知らせ

MN-166

MN-166のALS治療適応に対する欧州委員会のオーファンドラッグ指定のお知らせ

MN-166

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

MN-001

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001(Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Investor Relations
      • Press Release
      • Event
      • Media Archive
      • Annual Report
      • SEC filing
      • Stock Quote -TSE
      • Stock Quote -Nasdaq
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
      • Corporate Governance
      • Information Request
    • Presentation
      • Corporate Presentation and Equity Research Analyst Reports
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Contact Us
  • MediciNova, Inc.